Examiner Ratings For Allergan PLC (NYSE:AGN)
Today, Bank of America Corp. emphasized its Buy rating on Allergan PLC (NYSE:AGN) with a value focus of $280.00.
There are 6 hold evaluations, 19 purchase appraisals on the stock.
The present agreement rating on Allergan PLC (NYSE:AGN) is Buy (Score: 2.76) with an accord target cost of $278.79 per share, a potential 40.04% upside.
Some late investigator appraisals incorporate
12/23/2016-Bank of America Corp. Repeated Rating of Buy.
12/23/2016-Deutsche Bank AG Reiterated Rating of Buy.
12/21/2016-Goldman Sachs Group Inc. was Downgraded by investigators at Goldman Sachs Group Inc. from a "Conviction-Buy " rating to a " Buy" rating.
12/8/2016-Piper Jaffray Cos. Repeated Rating of Neutral.
12/6/2016-Argus Reiterated Rating of Buy.
Profit data for Allergan PLC (NYSE:AGN)
Allergan PLC (NYSE:AGN) pays a yearly profit of $0.00 with a yield of 0.00% and a normal profit development of - 37.00% in light of a 3 Year Average..
Profit History for Allergan PLC (NYSE:AGN)
On 11/2/2016 Allergan PLC declared a quarterly profit of $0.70 with an ex profit date of which will be payable on 3/28/2017.
On 2/4/2015 Allergan PLC declared a quarterly profit of $0.05 0.09% with an ex profit date of 2/5/2015 which will be payable on 3/20/2015.
On 10/27/2014 Allergan PLC declared a quarterly profit of $0.05 with an ex profit date of which will be payable on 12/11/2014.
On 7/28/2014 Allergan PLC declared a quarterly profit of $0.05 0.12% with an ex profit date of 8/13/2014 which will be payable on 9/5/2014.
On 5/7/2014 Allergan PLC declared a quarterly profit of $0.05 0.12% with an ex profit date of 5/21/2014 which will be payable on 6/13/2014.
On 2/5/2014 Allergan PLC declared a quarterly profit of $0.05 0.17% with an ex profit date of 2/26/2014 which will be payable on 3/21/2014.
On 10/30/2013 Allergan PLC declared a quarterly profit of $0.05 0.22% with an ex profit date of 11/18/2013 which will be payable on 12/11/2013.
Late Insider Trading Activity For Allergan PLC (NYSE:AGN)
Allergan PLC (NYSE:AGN) has insider responsibility for and institutional responsibility for.
On 12/8/2016 Nesli Basgoz, Director, sold 500 with a normal share cost of $188.72 per share and the aggregate exchange adding up to $94,360.00.
On 11/21/2016 Brent L. Saunders, CEO, purchased 5,250 with a normal share cost of $189.13 per share and the aggregate exchange adding up to $992,932.50.
On 11/11/2016 Maria Teresa Hilado, CFO, purchased 1,422 with a normal share cost of $210.64 per share and the aggregate exchange adding up to $299,530.08.
On 6/2/2016 Maria Teresa Hilado, CFO, purchased 661 with a normal share cost of $241.57 per share and the aggregate exchange adding up to $159,677.77.
On 5/11/2016 Nesli Basgoz, Director, sold 459 with a normal share cost of $225.10 per share and the aggregate exchange adding up to $103,320.90.
On 12/7/2015 Nesli Basgoz, Director, sold 2,300 with a normal share cost of $312.96 per share and the aggregate exchange adding up to $719,808.00.
About Allergan PLC (NYSE:AGN)
Allergan, Inc. is a multi-claim to fame social insurance organization. The Company concentrates on creating and commercializing pharmaceuticals, biologics, therapeutic gadgets and over-the-counter (OTC) items. It finds, creates and popularizes a scope of items for the ophthalmic, neurological, restorative style, medicinal dermatology, bosom feel, urological and other strength markets. The Company works in two sections: forte pharmaceuticals and therapeutic gadgets. The claim to fame pharmaceuticals fragment produces items, including ophthalmic items for dry eye, glaucoma, irritation, contamination, hypersensitivity and retinal illness; Botox for restorative and tasteful signs; healthy skin items for skin inflammation, psoriasis, eyelash development and solution and OTC skin health management items, and urologics items. The medicinal gadgets portion produces restorative gadgets, including bosom inserts for expansion, correction and reconstructive surgery and tissue expanders, and facial style items.
Late Trading Activity for Allergan PLC (NYSE:AGN)
Shares of Allergan PLC shut the past exchanging session at 199.08 up +5.09 2.62% with 4,179,664 shares exchanging hands.
Today, Bank of America Corp. emphasized its Buy rating on Allergan PLC (NYSE:AGN) with a value focus of $280.00.
There are 6 hold evaluations, 19 purchase appraisals on the stock.
The present agreement rating on Allergan PLC (NYSE:AGN) is Buy (Score: 2.76) with an accord target cost of $278.79 per share, a potential 40.04% upside.
Some late investigator appraisals incorporate
12/23/2016-Bank of America Corp. Repeated Rating of Buy.
12/23/2016-Deutsche Bank AG Reiterated Rating of Buy.
12/21/2016-Goldman Sachs Group Inc. was Downgraded by investigators at Goldman Sachs Group Inc. from a "Conviction-Buy " rating to a " Buy" rating.
12/8/2016-Piper Jaffray Cos. Repeated Rating of Neutral.
12/6/2016-Argus Reiterated Rating of Buy.
Profit data for Allergan PLC (NYSE:AGN)
Allergan PLC (NYSE:AGN) pays a yearly profit of $0.00 with a yield of 0.00% and a normal profit development of - 37.00% in light of a 3 Year Average..
Profit History for Allergan PLC (NYSE:AGN)
On 11/2/2016 Allergan PLC declared a quarterly profit of $0.70 with an ex profit date of which will be payable on 3/28/2017.
On 2/4/2015 Allergan PLC declared a quarterly profit of $0.05 0.09% with an ex profit date of 2/5/2015 which will be payable on 3/20/2015.
On 10/27/2014 Allergan PLC declared a quarterly profit of $0.05 with an ex profit date of which will be payable on 12/11/2014.
On 7/28/2014 Allergan PLC declared a quarterly profit of $0.05 0.12% with an ex profit date of 8/13/2014 which will be payable on 9/5/2014.
On 5/7/2014 Allergan PLC declared a quarterly profit of $0.05 0.12% with an ex profit date of 5/21/2014 which will be payable on 6/13/2014.
On 2/5/2014 Allergan PLC declared a quarterly profit of $0.05 0.17% with an ex profit date of 2/26/2014 which will be payable on 3/21/2014.
On 10/30/2013 Allergan PLC declared a quarterly profit of $0.05 0.22% with an ex profit date of 11/18/2013 which will be payable on 12/11/2013.
Late Insider Trading Activity For Allergan PLC (NYSE:AGN)
Allergan PLC (NYSE:AGN) has insider responsibility for and institutional responsibility for.
On 12/8/2016 Nesli Basgoz, Director, sold 500 with a normal share cost of $188.72 per share and the aggregate exchange adding up to $94,360.00.
On 11/21/2016 Brent L. Saunders, CEO, purchased 5,250 with a normal share cost of $189.13 per share and the aggregate exchange adding up to $992,932.50.
On 11/11/2016 Maria Teresa Hilado, CFO, purchased 1,422 with a normal share cost of $210.64 per share and the aggregate exchange adding up to $299,530.08.
On 6/2/2016 Maria Teresa Hilado, CFO, purchased 661 with a normal share cost of $241.57 per share and the aggregate exchange adding up to $159,677.77.
On 5/11/2016 Nesli Basgoz, Director, sold 459 with a normal share cost of $225.10 per share and the aggregate exchange adding up to $103,320.90.
On 12/7/2015 Nesli Basgoz, Director, sold 2,300 with a normal share cost of $312.96 per share and the aggregate exchange adding up to $719,808.00.
About Allergan PLC (NYSE:AGN)
Allergan, Inc. is a multi-claim to fame social insurance organization. The Company concentrates on creating and commercializing pharmaceuticals, biologics, therapeutic gadgets and over-the-counter (OTC) items. It finds, creates and popularizes a scope of items for the ophthalmic, neurological, restorative style, medicinal dermatology, bosom feel, urological and other strength markets. The Company works in two sections: forte pharmaceuticals and therapeutic gadgets. The claim to fame pharmaceuticals fragment produces items, including ophthalmic items for dry eye, glaucoma, irritation, contamination, hypersensitivity and retinal illness; Botox for restorative and tasteful signs; healthy skin items for skin inflammation, psoriasis, eyelash development and solution and OTC skin health management items, and urologics items. The medicinal gadgets portion produces restorative gadgets, including bosom inserts for expansion, correction and reconstructive surgery and tissue expanders, and facial style items.
Late Trading Activity for Allergan PLC (NYSE:AGN)
Shares of Allergan PLC shut the past exchanging session at 199.08 up +5.09 2.62% with 4,179,664 shares exchanging hands.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.